| Dear Paul, Precision medicine just took a HUGE step forward… CRISPR gene-editing technology was used on humans for the first time. Biotech company Intellia Therapeutics Inc. (Nasdaq: NTLA) achieved the milestone in a clinical trial in June. CRISPR editing was used to treat people with a rare protein disorder. Not only was the treatment safe, but preliminary results were also promising. Participants who received the highest dose saw an 87% drop in the therapy’s targeted protein. CRISPR has been the biggest development from the biotech industry in recent years. So much so that its pioneers received a Nobel Prize in 2020. And for good reason... It means no more monthly trips to the doctor.
From Our Friends at Laissez Faire. World's Second-Richest Man's NEW World-Changing Disruption
 In 1997, a relatively unknown man disrupted the retail industry.
Today, as the world's second-richest man, he is all set to disrupt another $2 trillion industry.
If you missed taking advantage of the retail disruption... Don't miss this!
You can get the full story right here packed with aerial images, important dates and even rare patent pics.
To see how this NEW disruption, can help you make a small fortune, click here.
The Gene-Editing Industry Is Growing Rapidly CRISPR technology targets common diseases where people inherit the wrong genes. It aims to cure these diseases by replacing faulty genes with healthy variant. This gets to the root of the problem: fixing the gene for good. But past CRISPR trials had one common problem. Since the technology was applied to genomes removed from the human body, certain cell types died off and lost function when grown in an artificial environment. Gene editing inside the human body (in vivo) can mitigate this problem by revising the genome in its native tissue. Scientists believe Intellia's in vivo geneediting results open the door to treating a wider range of diseases, including HIV. This is a BIG deal! Intellia’s stock doubled in a matter of days after its announcement. NTLA Soared Over 100% Last Week 
(Source: Bloomberg.) But if you missed out on Intellia’s rise, there’s no need to sweat. CRISPR gene editing is just a subset of the rapidly growing genomics market. This industry is poised to more than triple between now and 2030. 
(Source: Precedence Research.) To get exposure to the genomics industry, you can buy shares of the Global X Genomics and Biotechnology ETF (Nasdaq: GNOM). Or… You can join our Strategic Fortunes subscribers and find out about our favorite stock pick leading the genomic revolution. Regards,
Steve Fernandez
Research Analyst, Strategic Fortunes  
    Privacy Policy
Smart Profits Daily, P.O. Box 8378, Delray Beach, FL 33482.
To unsubscribe from Smart Profits Daily emails, click here.
To ensure that you receive future issues of Smart Profits Daily, please add info@mb.banyanhill.com to your address book or whitelist within your spam settings. For customer service questions or issues, please contact us for assistance.
The mailbox associated with this email address is not monitored, so please do not reply. Your feedback is very important to us so if you would like to contact us with a question or comment, please click here: http://banyanhill.com/contact-us
Legal Notice: This work is based on what we've learned as financial journalists. It may contain errors and you should not base investment decisions solely on what you read here. It's your money and your responsibility. Nothing herein should be considered personalized investment advice. Although our employees may answer general customer service questions, they are not licensed to address your particular investment situation. Our track record is based on hypothetical results and may not reflect the same results as actual trades. Likewise, past performance is no guarantee of future returns. Certain investments carry large potential rewards but also large potential risk. Don't trade in these markets with money you can't afford to lose. Banyan Hill Publishing expressly forbids its writers from having a financial interest in their own securities or commodities recommendations to readers. Such recommendations may be traded, however, by other editors, Banyan Hill Publishing, its affiliated entities, employees, and agents, but only after waiting 24 hours after an internet broadcast or 72 hours after a publication only circulated through the mail.
(c) 2021 Banyan Hill Publishing. All Rights Reserved. Protected by copyright laws of the United States and treaties. This Newsletter may only be used pursuant to the subscription agreement. Any reproduction, copying, or redistribution, (electronic or otherwise) in whole or in part, is strictly prohibited without the express written permission of Banyan Hill Publishing. P.O. Box 8378, Delray Beach, FL 33482. (TEL: 866-584-4096)
| 
No comments:
Post a Comment